TG Therapeutics (TGTX)

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Aksjekursen TG Therapeutics, Inc. Common Stock (TGTX) after-hours i dag er 28,89 $, som gjenspeiler en bevegelse på −1,80 % after-hours siden markedet sist stengte. Selskapets markedsverdi er $ 4,59 mrd., med et daglig handelsvolum på $ 1,97 mill. aksjer. For investorer som følger kursutviklingen, har TG Therapeutics, Inc. Common Stock-aksjen ligget mellom 28,39 $  og 29,46 $ i dag. Den forrige lukkekursen var 29,42 $.

Er du klar til å komme i gang? Følg trinnene nedenfor, eller les vår guide om hvordan kjøpe TG Therapeutics aksje på Kraken fra $10.